Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy

Cancer

Volumn 77, Issue 9, 1996, Pages 1912-1917

  Quiros, Peter A ^a   Kacinski, Barry M ^a,b   Wilson, Lynn D ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

cutaneous T cell lymphoma; extent of skin involvement; Mycosis fungoides; Sezary syndrome; T3; total skin electron beam therapy; tumor stage

Indexed keywords

CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; STEROID;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER SURVIVAL; DRY SKIN; ELECTRON BEAM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PUVA; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGED; BODY SURFACE AREA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SKIN; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0029966489     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1912::AID-CNCR23>3.0.CO;2-1     Document Type: Article

References (26)

1. Patterson J, Edelson R. Cutaneous T-cell lymphoma and other leukemic and lymphomatous infiltrates of the skin. In: Fitzpatrick TE, Eisen AZ, Wolff K, Arndt KA, Van Scott EJ, Vaughan JH, editors. Dermatology in general medicine. New York: McGraw-Hill, 1987:1086-118.
2. Braverman IM. Cutaneous T-cell lymphoma. Curr Probl Dermatol 1991;3:181-233.
3. Nasu K, Said J, Vonderheid E, Olerud J, Sako D, Kadin M. Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 1985;119:436-47.
4. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
5. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas: mycosis fungoides and the Sézary syndrome. Ann Intern Med 1994; 121:592-602.
6. Tadros AAM, Tepperman BS, Hryniuk WM, Peters VG, Rosenthal D, Roberts JT, et al. Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors. Int J Radiat Oncol Biol Phys 1983;9:1279-87.
7. Hoppe RT, Fuks Z, Bagshaw MA. Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:625-32.
8. Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA treatment of erythrodermic and plaque-type mycosis fungoides: ten year follow-up. Arch Dermatol 1987;123:897-901.
9. Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T-cell lymphomas. J Am Acad Dermatol 1984;10:238-45.
10. Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin O 1990;26:144-7.
11. Fuks ZY, Bagshaw MA. Total skin electron beam treatment of mycosis fungoides. Radiology 1971;100:145-50.
12. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-803.
13. Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:725-8.
14. Kennedy CTC. Reactions to mechanical and thermal injury. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 5th ed. Oxford: Blackwell Scientific Publications; 1992:812-13.
15. Licata A, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma: the influence of additional therapy after total skin electron beam radiation. Arch Dermatol 1195;131:432-5.
16. Braverman IM, Yager NB, Chen M, Cadman EC, Hait WN, Maynard T. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 1987;16:45-60.
17. Abel EA, Deneau DG, Farber EM, Price NM, Hoppe RT. PUVA treatment of erythrodermic and plaque type mycosis fungoides. J Am Acad Dermatol 1981;4:423-9.
18. Spittle MF. Electron beam therapy in England. Cancer Treat Rep 1979;63:639-41.
19. Edelson RL, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.
20. Heald P, Edelson RL. Photophoresis for T-cell mediated diseases. Adv Dermatol 1988;3:25-40.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Wilson LD, Licata A, Braverman IM, Edelson RC, Heald PW, Feldman AM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995;32:987-95.
23. Fuks ZY, Bagshaw MA, Farber EM. Prognostic signs and the management of the mycosis fungoides. Cancer 1973;32: 1385-95.
24. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990;15:292-357.
25. Wilson LD, Cooper DL, Goodrich AL, Friedman ND, Feldman AM, Braverman IM, et al. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys 1994;28:829-37.
26. Hoppe RT, Cox RS, Fuks Z, Price WM, Bagshaw MA, Farber EM. Electron beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979;63:691-700.